<DOC>
	<DOCNO>NCT01470313</DOCNO>
	<brief_summary>This study design evaluate safety tolerability multiple intravenously administer dos PD-0360324 patient cutaneous lupus erythematosus . Changes disease activity also evaluate .</brief_summary>
	<brief_title>A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus</brief_title>
	<detailed_description>The trial terminate prematurely Oct 15 , 2013 due business decision . The decision terminate trial base clinical safety efficacy concern .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Lupus Erythematosus , Cutaneous</mesh_term>
	<criteria>Male and/or female subject age 21 70 clinical diagnosis either discoid cutaneous lupus erythematosus subacute cutaneous lupus erythematosus without systemic lupus erythematosus prior screen confirm evaluation skin biopsy sample . Active disease screen baseline ( Day 1 ) define CLASI score great equal 10 . Intolerance antimalarial therapy 3 month antimalarial therapy disease activity . Use great equal 20 mg prednisone ( equivalent ) within 3 month Day 1 . Signs symptoms relevant history viral , bacterial , fungal , parasitic infection , recent history repeat infection Subjects evidence past active tuberculosis Pregnant , plan get pregnant , and/or lactating female male plan father child within time period study subsequent exclusionary period .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Safety tolerability</keyword>
	<keyword>cutaneous lupus erythematosus</keyword>
	<keyword>efficacy</keyword>
</DOC>